Provider Briefing: Prempro 0.625/5 28 Day Availability in 2026

If your patients have been reporting difficulty filling Prempro 0.625/5 28 Day prescriptions, the reports are consistent with a broader pattern of supply inconsistency for this medication. While Prempro has not been formally listed as a sustained FDA drug shortage, availability at the pharmacy level has been unreliable — particularly for the 0.625/5 mg strength, which is the highest dose and least commonly stocked formulation.

This article provides a concise overview of the current situation, prescribing implications, therapeutic alternatives, and practical tools to help your patients maintain access to appropriate hormone replacement therapy.

Timeline: How We Got Here

Prempro (conjugated estrogens 0.625 mg / medroxyprogesterone acetate 5 mg) has been on the market since 1995, manufactured by Wyeth (now Pfizer). Following the 2002 Women's Health Initiative (WHI) findings — which demonstrated increased cardiovascular and breast cancer risk with combination estrogen-progestin therapy — prescribing of Prempro and similar HRT products declined sharply.

Key milestones:

• 2002: WHI estrogen-plus-progestin arm halted early due to increased risks of breast cancer, heart disease, stroke, and blood clots. Prempro prescriptions declined by over 50% in the following years.
• 2010s: Medical consensus evolved. Professional societies including NAMS (North American Menopause Society) and ACOG began supporting HRT for appropriate patients — particularly symptomatic women under 60 or within 10 years of menopause onset.
• 2020s: Rising interest in menopause care and hormone therapy drove some prescribing recovery, but Prempro volumes remained well below pre-WHI levels. Production volumes were scaled accordingly.
• 2024-2026: Sporadic availability issues emerged as production runs for the highest-dose formulation (0.625/5 mg) didn't consistently meet demand at the pharmacy level.

Prescribing Implications

The availability challenges with Prempro 0.625/5 have several practical implications for prescribers:

Patient Adherence Risk

When patients can't fill their HRT prescription on time, they face symptom recurrence — hot flashes, night sweats, sleep disruption, and vaginal atrophy symptoms can return within days of discontinuation. Abrupt cessation also carries a theoretical risk of rebound vasomotor symptoms.

No Therapeutic Substitution at Pharmacy Level

Pharmacists cannot therapeutically substitute a different HRT product without prescriber authorization. If Prempro 0.625/5 is unavailable, the patient will need a new prescription unless your state allows a specific substitution pathway. This creates a bottleneck that delays treatment.

Dose-Specific Stocking

Prempro is available in four strengths (0.3/1.5, 0.45/1.5, 0.625/2.5, and 0.625/5 mg). The 0.625/5 mg strength is the least commonly dispensed, making it the most vulnerable to stocking gaps. Consider whether a lower dose would be clinically appropriate — dose reduction may improve both availability and the patient's risk profile.

Current Availability Picture

As of early 2026:

• Prempro 0.625/5 mg is manufactured solely by Pfizer
• There is no FDA-approved AB-rated generic
• Availability varies significantly by region and pharmacy chain
• Independent pharmacies and mail-order services tend to have better stock than large chains
• Wholesaler-level supply appears to exist, but pharmacies may not carry the 0.625/5 strength routinely due to low turnover

Cost and Access Considerations

The absence of a generic creates both availability and affordability challenges:

• Cash price: $250–$450 per 28-tablet pack
• Insurance: Typically placed on Tier 3 (non-preferred brand), with copays often $50–$100+
• Prior authorization: Some plans require PA or step therapy through lower-cost HRT options before covering Prempro
• Patient assistance: Pfizer RxPathways (pfizerrxpathways.com) offers support for qualifying patients

For patients facing cost barriers, our provider guide to helping patients save money on Prempro provides detailed strategies.

Tools and Resources for Providers

Medfinder for Providers

Medfinder is a real-time medication availability tool that helps patients locate pharmacies with hard-to-find medications in stock. You can direct patients to medfinder.com or use the provider dashboard at medfinder.com/providers to streamline the process from your practice.

Prescribing Strategies

Consider building the following into your workflow:

• Proactive alternatives: When writing a Prempro prescription, note an approved alternative on the chart in case the primary medication is unavailable
• Component prescribing: Prescribe Premarin 0.625 mg + generic medroxyprogesterone acetate 5 mg as a backup — same active ingredients, potentially easier to source
• Dose evaluation: For patients stable on 0.625/5 mg, evaluate whether a step-down to 0.625/2.5 mg would maintain symptom control with better availability
• E-prescribing flexibility: Include a note to the pharmacist allowing contact for therapeutic alternatives if the prescribed product is unavailable

Alternative Agents

When Prempro is unavailable, consider these evidence-based alternatives:

• Activella / generic estradiol-norethindrone acetate — continuous combined oral HRT with wide generic availability
• Bijuva (estradiol/progesterone) — bio-identical combination capsule, once daily
• CombiPatch (estradiol/norethindrone transdermal) — combination patch, applied twice weekly; may be preferred for patients with VTE risk factors given lower first-pass hepatic exposure
• Premarin + Provera prescribed separately — identical active ingredients to Prempro, individually sourced

Looking Ahead

The Prempro supply situation is unlikely to change dramatically in the near term. Without generic competition and with a single manufacturer, the supply chain remains inherently fragile. However, the broader HRT landscape continues to evolve, with increasing availability of estradiol-based and bio-identical options that provide clinically appropriate alternatives.

Proactive prescribing — including backup plans, dose optimization, and patient education about availability tools — is the most effective strategy for ensuring continuity of care.

Final Thoughts

Prempro 0.625/5 28 Day remains a useful and FDA-approved option for menopausal hormone therapy, but its single-source supply and lack of generic competition create real access challenges for patients. By staying informed about the current availability landscape, having alternative prescribing strategies ready, and directing patients to tools like Medfinder, providers can help minimize treatment disruptions.

For a complementary resource, see our guide: How to Help Your Patients Find Prempro 0.625/5 28 Day in Stock.